Fig. 2: Cumulative incidence of all-cause hospitalization in nirmatrelvir/ritonavir and control groups over the 28 days period. | Nature Communications

Fig. 2: Cumulative incidence of all-cause hospitalization in nirmatrelvir/ritonavir and control groups over the 28 days period.

From: Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Fig. 2

Line plot represents the cumulative incidence of all-cause hospitalization in nirmatrelvir/ritonavir (blue line) and control groups (red line) over the 28 days follow-up period. Shaded regions represent 95% confidence bands calculated using 500 bootstrap replicates. Table represents number at risk in nirmatrelvir/ritonavir and control groups after cloning. Over 28 days of follow-up, the cumulative incidences of all-cause hospitalization were 0.45% and 0.68% among nirmatrelvir/ritonavir users and non-users, respectively.

Back to article page